Risk of Acne in Patients With Atopic Dermatitis Starting a JAK Inhibitor vs Th2 Cytokine Inhibitor.
Saved in:
| Title: | Risk of Acne in Patients With Atopic Dermatitis Starting a JAK Inhibitor vs Th2 Cytokine Inhibitor. |
|---|---|
| Authors: | Schneeweiss MC; Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Wyss R; Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Anand P; Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Jin Y; Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Mostaghimi A; Harvard Medical School, Boston, Massachusetts.; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts., Barbieri JS; Harvard Medical School, Boston, Massachusetts.; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.; Associate Editor, JAMA Dermatology., Merola JF; Division of Rheumatology, Department of Dermatology and Department of Medicine, UT Southwestern Medical Center and O'Donnell School of Public Health, Dallas, Texas., Silverberg JI; Department of Dermatology, George Washington University, Washington, DC., Rosmarin DM; Department of Dermatology, Indiana University, Indianapolis., Glynn RJ; Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Schneeweiss S; Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts. |
| Source: | JAMA dermatology [JAMA Dermatol] 2026 Mar 01; Vol. 162 (3), pp. 313-316. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6084 |
|---|---|
| DOI: | 10.1001/jamadermatol.2025.5443 |
